These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

848 related articles for article (PubMed ID: 15709168)

  • 1. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.
    Ogishima T; Shiina H; Breault JE; Tabatabai L; Bassett WW; Enokida H; Li LC; Kawakami T; Urakami S; Ribeiro-Filho LA; Terashima M; Fujime M; Igawa M; Dahiya R
    Clin Cancer Res; 2005 Feb; 11(3):1028-36. PubMed ID: 15709168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancer.
    Ogishima T; Shiina H; Breault JE; Terashima M; Honda S; Enokida H; Urakami S; Tokizane T; Kawakami T; Ribeiro-Filho LA; Fujime M; Kane CJ; Carroll PR; Igawa M; Dahiya R
    Oncogene; 2005 Oct; 24(45):6765-72. PubMed ID: 16007175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer.
    Enokida H; Shiina H; Igawa M; Ogishima T; Kawakami T; Bassett WW; Anast JW; Li LC; Urakami S; Terashima M; Verma M; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
    Cancer Res; 2004 Sep; 64(17):5956-62. PubMed ID: 15342374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer.
    Zhao H; Shiina H; Greene KL; Li LC; Tanaka Y; Kishi H; Igawa M; Kane CJ; Carroll P; Dahiya R
    Cancer; 2005 Jul; 104(1):44-52. PubMed ID: 15895377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer.
    Tokizane T; Shiina H; Igawa M; Enokida H; Urakami S; Kawakami T; Ogishima T; Okino ST; Li LC; Tanaka Y; Nonomura N; Okuyama A; Dahiya R
    Clin Cancer Res; 2005 Aug; 11(16):5793-801. PubMed ID: 16115918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylation mediated silencing of TMS1/ASC gene in prostate cancer.
    Das PM; Ramachandran K; Vanwert J; Ferdinand L; Gopisetty G; Reis IM; Singal R
    Mol Cancer; 2006 Jul; 5():28. PubMed ID: 16848908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling.
    Kim YJ; Yoon HY; Kim SK; Kim YW; Kim EJ; Kim IY; Kim WJ
    Clin Cancer Res; 2011 Jul; 17(13):4523-30. PubMed ID: 21571867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative assessment of AKAP12 promoter methylation in human prostate cancer using methylation-sensitive high-resolution melting: correlation with Gleason score.
    Liu W; Gong J; Hu J; Hu T; Sun Y; Du J; Sun C; Guan M; Jiang H; Lu Y
    Urology; 2011 Apr; 77(4):1006.e1-7. PubMed ID: 21310466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
    Henrique R; Costa VL; Cerveira N; Carvalho AL; Hoque MO; Ribeiro FR; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
    J Mol Med (Berl); 2006 Nov; 84(11):911-8. PubMed ID: 17016690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.
    Kelavkar UP; Harya NS; Hutzley J; Bacich DJ; Monzon FA; Chandran U; Dhir R; O'Keefe DS
    Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):185-97. PubMed ID: 17164146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparanase expression is associated with histone modifications in glioblastoma.
    Hong X; Nelson K; Lemke N; Kalkanis SN
    Int J Oncol; 2012 Feb; 40(2):494-500. PubMed ID: 22001963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of promoter methylation in regulation of the mammalian heparanase gene.
    Shteper PJ; Zcharia E; Ashhab Y; Peretz T; Vlodavsky I; Ben-Yehuda D
    Oncogene; 2003 Oct; 22(49):7737-49. PubMed ID: 14586400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
    Guan M; Zhou X; Soulitzis N; Spandidos DA; Popescu NC
    Clin Cancer Res; 2006 Mar; 12(5):1412-9. PubMed ID: 16533763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells.
    Singal R; van Wert J; Bashambu M
    Cancer Res; 2001 Jun; 61(12):4820-6. PubMed ID: 11406558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase and DNA methyltransferase in human prostate cancer.
    Patra SK; Patra A; Dahiya R
    Biochem Biophys Res Commun; 2001 Sep; 287(3):705-13. PubMed ID: 11563853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer.
    Jarrard DF; Bova GS; Ewing CM; Pin SS; Nguyen SH; Baylin SB; Cairns P; Sidransky D; Herman JG; Isaacs WB
    Genes Chromosomes Cancer; 1997 Jun; 19(2):90-6. PubMed ID: 9171999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer.
    Vanaja DK; Ballman KV; Morlan BW; Cheville JC; Neumann RM; Lieber MM; Tindall DJ; Young CY
    Clin Cancer Res; 2006 Feb; 12(4):1128-36. PubMed ID: 16489065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer.
    Shiina H; Breault JE; Basset WW; Enokida H; Urakami S; Li LC; Okino ST; Deguchi M; Kaneuchi M; Terashima M; Yoneda T; Shigeno K; Carroll PR; Igawa M; Dahiya R
    Cancer Res; 2005 Mar; 65(6):2130-8. PubMed ID: 15781623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway.
    Urakami S; Shiina H; Enokida H; Kawakami T; Tokizane T; Ogishima T; Tanaka Y; Li LC; Ribeiro-Filho LA; Terashima M; Kikuno N; Adachi H; Yoneda T; Kishi H; Shigeno K; Konety BR; Igawa M; Dahiya R
    Clin Cancer Res; 2006 Jan; 12(2):383-91. PubMed ID: 16428476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CpG hypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma.
    Nojima D; Li LC; Dharia A; Perinchery G; Ribeiro-Filho L; Yen TS; Dahiya R
    Cancer; 2001 Oct; 92(8):2076-83. PubMed ID: 11596023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.